A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引：44

作者：

Bekker, PJ

Holloway, DL

Rasmussen, AS

Murphy, R

Martin, SW

Leese, PT

Holmes, GB

Dunstan, CR

DePaoli, AM

机构：

[1] Amgen Inc, Newbury Pk, CA 91320 USA

[2] Quintiles, Lenexa, KS USA

[3] SFBC Int Inc, Miami, FL USA

[4] ANZAC Res Inst, Concord, NSW, Australia

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2005年 / 20卷 / 12期

关键词：

RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;

D O I：

10.1359/jbmr.2005.20.12.2274

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.

引用

页码：2274 / 2282

页数：9

共 50 条

[41] RANK ligand and osteoprotegerin in myeloma bone disease
Sezer, O
Heider, U
Zavrski, I
Kühne, CA
Hofbauer, LC
[J]. BLOOD, 2003, 101 (06) : 2094 - 2098
[42] Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
Simonet, WS
Lacey, DL
Dunstan, CR
Kelley, M
Chang, MS
Luthy, R
Nguyen, HQ
Wooden, S
Bennett, L
Boone, T
Shimamoto, G
DeRose, M
Elliott, R
Colombero, A
Tan, HL
Trail, G
Sullivan, J
Davy, E
Bucay, N
RenshawGegg, L
Hughes, TM
Hill, D
Pattison, W
Campbell, P
Sander, S
Van, G
Tarpley, J
Derby, P
Lee, R
Boyle, WJ
[J]. CELL, 1997, 89 (02) : 309 - 319
[43] Mutation screening of the TNFRSF11A gene encoding receptor activator of NFκB (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma
Sparks, AB
Peterson, SN
Bell, C
Loftus, BJ
Hocking, L
Cahill, DP
Frassica, FJ
Streeten, EA
Levine, MA
Fraser, CM
Adams, MD
Broder, S
Venter, JC
Kinzler, KW
Vogelstein, B
Ralston, SH
[J]. CALCIFIED TISSUE INTERNATIONAL, 2001, 68 (03) : 151 - 155
[44] Breast cancer cells interact with osteoblasts to support osteoclast formation
Thomas, RJ
Guise, TA
Yin, JJ
Elliott, J
Horwood, NJ
Martin, TJ
Gillespie, MT
[J]. ENDOCRINOLOGY, 1999, 140 (10) : 4451 - 4458
[45] Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women
Tonino, RP
Meunier, PJ
Emkey, R
Rodriguez-Portales, JA
Menkes, CJ
Wasnich, RD
Bone, HG
Santora, AC
Wu, M
Desai, R
Ross, PD
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09) : 3109 - 3115
[46] Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
Tsuda, E
Goto, M
Mochizuki, S
Yano, K
Kobayashi, F
Morinaga, T
Higashio, K
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 234 (01) : 137 - 142
[47] Osteoprotegerin deficiency and juvenile Paget's disease
Whyte, MP
Obrecht, SE
Finnegan, PM
Jones, JL
Podgornik, MN
McAlister, WH
Mumm, S
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (03) : 175 - 184
[48] Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, SR
Schooley, K
Smolak, PJ
Din, WS
Huang, CP
Nicholl, JK
Sutherland, GR
Smith, TD
Rauch, C
Smith, CA
Goodwin, RG
[J]. IMMUNITY, 1995, 3 (06) : 673 - 682
[49] Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H
Shima, N
Nakagawa, N
Yamaguchi, K
Kinosaki, M
Mochizuki, S
Tomoyasu, A
Yano, K
Goto, M
Murakami, A
Tsuda, E
Morinaga, T
Higashio, K
Udagawa, N
Takahashi, N
Suda, T
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) : 3597 - 3602
[50] Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
Zhang, J
Dai, JL
Qi, YH
Lin, DL
Smith, P
Strayhorn, C
Mizokami, A
Fu, Z
Westman, J
Keller, ET
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (10) : 1235 - 1244

← 1 2 3 4 5 →